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Heart failure (HF) currently affects 6.5 million adults in the
United States (1), and its prevalence is projected to increase
by 25% by 2030 (2). Hospitalization represents a turning
point in the natural history of HF, with a combined
mortality and readmission rate of 30% within 90 days
post-discharge; one-quarter of patients are readmitted within
30 days (3,4). Hospitalizations are responsible for the
majority of the $39 billion spent annually for HF care (5). It
is not surprising therefore that HF hospitalization is a focal
point for quality improvement (QI) and cost reduction
attempts. The Centers for Medicare & Medicaid Services
(CMS) has mandated reporting of hospital-level 30-day
readmission rates for HF and acute myocardial infarction
(AMI) in an effort to improve outcomes (6). Public report-
ing of outcomes as hospital performance indicators and
incentive for improvement has not always proved to be
effective, and public reporting has had a minor effect on
outcomes (7,8). The escalation of this paradigm to deny
payment for readmission within 30 days of discharge has
been a game changer and has resulted in a widespread
concern across hospitals.
See page 607
What are the hospitals doing to meet this challenge? In
this issue of the Journal, Bradley et al. (9) report the results
of a survey to describe the practices employed by hospitals
enrolled in the Hospital to Home (H2H) QI initiative to
reduce readmissions for HF or AMI. The response rate of
90.4% reflects the strong motivation of the participating
hospitals. The reported practices focused on resources and
performance monitoring, medication management, and dis-
charge planning and follow-up care. Eighty-seven percent
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this paper to disclose.of hospitals had a QI team, and professionals with diverse
backgrounds staffed them. Hospitals tracked a variety of
metrics and employed various approaches for medication
reconciliation and discharge planning. These findings high-
light that hospitals invest significant resources for QI. It is
striking that hospital practices are diverse and adoption rates
variable. There are some inherent limitations of this survey
that the investigators acknowledged. However, the purpose
of this survey was to scan the environment, and the results
provide valuable information.
The overarching question, however, is not what the
hospitals are doing to prevent HF readmission, but why are
they doing it and what is the evidence that these interven-
tions are effective and cost-effective? The answer to why is
simple, because they are compelled to do so. The perspective
of pay-for-performance is a strong incentive for action.
However, the underlying logic model has several assump-
tions that link the program activities to short- and long-
term impact. In the case of QI programs to reduce HF
readmissions, this logic model is weak. The first assumption
is that program implementation will change actual practice;
however, increased documentation of quality metrics is not
synonymous with patient-level modification in practice (7).
he second assumption is that QI interventions will be
ffective irrespective of how they are implemented. Lastly, the
igger assumptions are that the short-term effect will affect
eadmission rates and that reduced readmissions will improve
uantity and the quality of life of patients, and reduce costs. It
s worth further examining these assumptions.
Does conformity with process of care measures improve
F outcomes? Not necessarily. Unless the link between
rocess of care and outcomes is strong, a QI program may
eliably improve compliance with process of care measures
ithout affecting outcomes. In OPTIMIZE-HF (Orga-
ized Program to Initiate Lifesaving Treatment in Hospi-
alized Patients With Heart Failure), only medications with
roven efficacy by randomized trials were associated with
mproved outcomes, but the processes based on expert
pinion or observational data were not (10). It is also
mportant to note that the underlying evidence base for
nterventions for AMI versus HF is quite different. HF is a
omplex disease, and what should work logically does not
lways work in practice. The barrage of negative trials in HF
uring the last decade highlights this. Could this be the case
ith the emerging shift towards discharge planning and its
arious components as the new focus of efforts to reduce HF
eadmission? This question is ultimately important consid-
ring the second assumption stated previously (i.e., inter-
entions are effective irrespective of the approach to imple-
entation). Could it be possible that the past expert
pinion-based logical interventions were not associated with
angible improvement in outcomes because of the vast
eterogeneity with which they were implemented across
nstitutions? What does it mean to give “discharge instruc-
ions to patients”: providing printed materials, a nurse
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the patient, or a multidisciplinary team conducting a family
meeting? Understanding implementation is critical. Other-
wise, we might be misled by negative trials to believe that
the interventions are ineffective, whereas the problem is
with implementation.
Public reporting of discharge planning may have no effect
on outcomes (7). The notion that it is the discharge
planning “culture” that needs to be fixed has prompted large
national QI initiatives (11,12). The supporting data for early
follow-up comes from a meta-analysis (13) that mostly
included studies with actual home visits, and an observa-
tional report where early follow-up was associated with
reduced 30-day readmissions (14). The latter study did not
assess whether time-to-first-visit post-discharge was associ-
ated with readmission, but instead looked at quartiles of
patients who had clinic appointments within 7 days and
linked it to outcomes. There was no difference in readmis-
sion rates between quartiles 2 and 4, and the first quartile
showed a reduction by 2.7% only, which was likely influ-
enced by selection bias based on characteristics that led to
early follow-up. Of note, another study found no effect on
30-day or 6-month outcomes with early follow-up (15).
Evidence for medication reconciliation was also not conclu-
sive. In a randomized study of pharmacist-led intervention
to optimize HF therapy, there was no improvement in
outcomes (16). Similar experience was reported for patient
education, self-care, and symptom management. In a study
of disease-management programs funded by CMS costing
over $400 million, no reduction in utilization of acute care
or cost savings was demonstrated for patients with HF
and/or diabetes (17). These programs included nurse-based
call centers, health coaches to target persons at high risk for
adverse events, and intensive patient education using a
variety of resources to improve understanding of disease,
self-care, and communication with providers. Yet, despite
modest improvement in quality measures, no meaningful
impact on outcomes or costs was observed. In all, the
evidence supporting various forms of disease management
and early clinic follow-up to improve HF outcomes and
reduce costs to date is inadequate.
The literature is replete with interventions proven not
beneficial in trials despite encouraging observational data
and logic. In the case of HF, there are now 2 telemonitoring
and 1 self-care intervention trial that showed no benefit
(18–20). The only approved interventions that showed
improvement in post-discharge outcomes in acute HF were
randomized trial proven medical therapies for chronic HF
that can be implemented during admission to optimize care
(10). Otherwise, unlike AMI, there are currently no discrete
evidence-based interventions targeted at acute HF that have
been shown to improve post-discharge outcomes. How is it
possible that all these logical, good clinical practice inter-
ventions had no effect on outcomes? Does it really make
sense to not follow-up patients after discharge or not
educate them? Of course not! However, these negative trialsnevertheless underscore the importance of carefully consid-
ering the implementation science behind these interventions
and focus not only on the right intervention, but also on the
right intervention on the right patients implemented in the
right manner, otherwise one will continue to risk negating
or diluting the benefits.
With weak evidence behind the surveyed processes of
care, promoting compliance with these activities is prema-
ture. These are expensive endeavors. Instead, funding sci-
ence to identify effective interventions might be a worthier
investment. Currently, hospitals are allocating considerable
resources on reducing HF readmissions by assuming that
simple causative processes underlie a very complex problem.
Tying a performance measure to reimbursement is guaran-
teed to improve the measure, one way or another. For HF,
it is unclear whether this will translate into improvement in
outcomes and costs. The assumption that most HF hospi-
talizations are preventable and may reflect suboptimal care
can be challenged (21,22).
Financial incentives are strong motivators, but the goals
achieved may not always be beneficial. For example, a trend
toward worsening post-discharge 30-day HF readmissions
was observed when incentives drove hospital length of stay
down (22). For some interventions, there is no way around
but to conduct randomized trials. However, there are
neither enough resources nor time to wait for such data to
be accrued in every case. However, this does not mean that
one should take observations as factual evidence. For inter-
ventions without an obvious downside (e.g., medication
reconciliation), it is fair to assess the intervention more in
the QI spirit of Plan-Do-Study-Act paradigm. However,
we have to study it. We should define and standardize the
intervention and develop pre-defined metrics for the effec-
tiveness of these activities. It is not uncommon that such
interventions are implemented across institutions, and across
different departments or units within a given institution,
without standardization or plans for how and which data will
be collected when to assess their effectiveness. They neverthe-
less are expensive and, without proper data collection regarding
their effectiveness and unintended consequences, we will never
know the subtleties and nuances of when they do and do not
work and how to improve them (Fig. 1).
In summary, Bradley et al. (9) should be congratulated for
a timely paper that describes important information. The
scope of activities recently spawned by the CMS decision to
not pay for early readmissions is overwhelming. Unfortu-
nately, many of these activities are neither proven nor
primarily based on the motivation to improve patient
outcomes, but rather on the fear of punitive financial
disincentives. Would these enormous resources spent by
hospitals to randomly implement unproven interventions be
better spent on actually studying what the real determinants
of HF hospitalizations are and which interventions will
prove to be beneficial? Such questions are difficult to answer
when policy trumps science. We agree with the investigators
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